We’ll also be hosting a panel discussion (free lunch!) with experts from the pharmaceutical industry and healthcare to academia, who will talk in-depth on how they are actually bringing together genomic and phenotypic data.
The premise of this panel is that the new bottleneck in genomics is colliding rich datasets (e.g. NGS data with phenotypic data). While we have moved beyond the challenges of reading, storing and processing DNA sequencing data, we have entered a new phase where the next wave of advancements will come from projects where diverse sources of data are integrated and interrogated collectively. The conversation will cover technical innovations and specific approaches with a focus on what is working and why, along with challenges encountered and how they are being addressed.
Lunch Panel Discussion Details
Title: Leveraging Genomic and Phenotypic Data to Advance Science and Improve Patient Care
When: Monday, October 20th, 12:30pm – 2pm (Lunch is on us! Join us to take a break and talk genomics.)
Where: Convention Center – Room #2, Upper Level
David Shaywitz, MD, PhD, DNAnexus CMO & Co-Author, Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology?
David Carey, PhD – Associate Chief Research Officer, Geisinger
Jeffrey Reid, PhD – Director and Head of Genome Informatics, Regeneron Genetics Center
Marylyn D. Ritchie, PhD – Director, Center for Systems Genomics; Professor, Biochemistry and Molecular Biology; Pennsylvania State University
William Salerno, PhD – Sr. Staff Scientist, Human Genome Sequencing Center, Baylor College of Medicine
You can also hear about DNAnexus in the following poster sessions:
Presenter: Andrew Carroll, PhD – Director of Science, DNAnexus
Investigating the relationship between allele frequency of benign variants used in training mutation impact predictors and overprediction of deleteriousness
Presenter: Singer Ma – Scientist, DNAnexus
Title: Reproducible and repurposable toolkit of structural variant callers applied to 3,751 whole genomes and 10,940 whole exome